The best indicator for ResMed (RMD)
We backtested 20 indicators across daily, weekly and hourly charts on real ResMed (RMD) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the daily chart, this is the strongest risk-adjusted edge we found for ResMed (RMD) over ~31.0 years — trailing buy-and-hold by 9.3% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stochastic ✓ | Daily | 11.6% | 0.59 | -55.7% | 69.3% | 150 | -9.3% |
| 2 | Williams %R ✓ | Daily | 12.0% | 0.59 | -66.3% | 66.0% | 194 | -8.9% |
| 3 | Williams %R ✓ | Weekly | 11.1% | 0.59 | -40.3% | 76.9% | 39 | -9.7% |
| 4 | EMA 50/200 Cross ✓ | Daily | 14.4% | 0.56 | -61.6% | 52.2% | 23 | -6.5% |
| 5 | WaveTrend (8/6/4) ✓ | Daily | 12.3% | 0.56 | -61.4% | 72.7% | 110 | -8.6% |
| 6 | SMA 50/200 Cross ✓ | Daily | 13.3% | 0.54 | -61.7% | 68.2% | 22 | -7.6% |
| 7 | Holy Grail Confluence ✓ | Daily | 10.1% | 0.54 | -52.4% | 86.0% | 50 | -10.8% |
| 8 | Stochastic ✓ | Weekly | 7.9% | 0.5 | -50.5% | 81.5% | 27 | -12.8% |
| 9 | Money Flow Index ✓ | Daily | 9.2% | 0.49 | -54.5% | 77.1% | 35 | -11.6% |
| 10 | EMA 20/50 Cross ✓ | Weekly | 14.7% | 0.58 | -56.5% | 66.7% | 12 | -6.0% |
| 11 | CCI ✓ | Daily | 8.2% | 0.44 | -55.0% | 70.1% | 144 | -12.6% |
| 12 | Bollinger Mean-Reversion ✓ | Weekly | 5.0% | 0.43 | -42.2% | 77.8% | 18 | -15.8% |
| 13 | CCI ✓ | Weekly | 7.0% | 0.43 | -50.5% | 80.0% | 30 | -13.8% |
| 14 | EMA-10 Trend ✓ | Weekly | 8.4% | 0.43 | -58.4% | 49.3% | 142 | -12.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For ResMed (RMD), Stochastic on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.